SARS-CoV-2 variants are evolving new ways to evade antibodies, vaccines

This article is part of Harvard Medical School’s continuing coverage of medicine, biomedical research, medical education, and policy related to the

Related Keywords

Australia ,Boston University ,Massachusetts ,United States ,America ,Amos Hostetter ,Jonathan Abraham ,Anthony Griffiths ,Katherine Nabel ,Lindsay Mckay ,National Emerging Infectious Diseases Laboratories ,National Center ,Harvard Pilgrim Health Care Institute ,Us Centers For Disease ,National Institutes Of Health ,Massachusetts Consortium On Pathogen Readiness ,Boston University School Of Medicine ,Harvard Medical School ,Abbvie Bioresearch Center ,Chleck Family Foundation ,Harvard Mit Program ,Blavatnik Institute ,Translational Science Center ,South America ,Phd Program ,Massachusetts General Hospital ,Public Health ,Boston University School ,Abbvie Bioresearch ,Massachusetts Consortium ,Pathogen Readiness ,Disease Control ,National Institutes ,Harvard Clinical ,Advancing Translational Science ,Chleck Family ,